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Abstract 
 
 
 
Hispanics are the largest and fastest-growing minority population in the United States, 
currently comprising about 16.3% (52 million) of the total population. With an increased 
prevalence of metabolic risk factors in this population, the rate of uncontrolled 
hypertension (HTN) in Hispanics significantly exceeds the rates observed among non-
Hispanic blacks and whites. Unfortunately, data on HTN in Hispanics remains limited 
due to the under-representation of Hispanics in clinical trials; with most of the data 
primarily restricted to observational and retrospective subgroup analyses. This article 
aims to review the available data on prevalence, awareness and control of HTN, risk 
factors and some of the challenges unique to the Hispanics population.  We also discuss 
treatment strategies derived from large HTN trials that included Hispanics. 
Abbreviations: ACE – angiotensin-converting enzyme ALLHAT – Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack ARB  - angiotensin receptor blocker BP – blood pressure CAD – coronary artery disease CV – cardiovascular CVD – cardiovascular disease DBP – diastolic blood pressure DM – Diabetes Mellitus HCTZ – hydrochlorothiazide hsCRP – highly sensitive C-reactive protein HTN – hypertension JNC – Joint National Council MetS – Metabolic syndrome MI – Myocardial infarction SBP – systolic blood pressure SR – sustained release T2DM – Type 2 Diabetes Mellitus 
US – United States 
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Introduction 
 
Hispanics, with an estimated population of 52 million, represent the largest minority 
group in the United States (US) and by 2050 are predicted to become the country’s   
majority population  with1 in 3 US residents being of Hispanic descent. (1) 
Epidemiological and population based data suggests that the rate of uncontrolled 
hypertension (HTN) in Hispanics significantly exceeds the rates observed among non-
Hispanic blacks and whites. (2) Approximately 29% of the adult US population carries 
the diagnosis of HTN (3) and with estimates suggesting that this number will continue to 
increase, HTN and its consequences will remain a major public health issue especially in 
Hispanics. In addition, Hispanics are more likely to be affected by obesity and type 2 
diabetes (T2D) when compared to non-Hispanic whites. (4) The higher prevalence of 
these cardiovascular (CV) risk factors further contributes to the increase morbidity and 
mortality associated with HTN in this population.  Unfortunately, data on HTN in 
Hispanics still remains limited due to their under-representation in clinical trials; with 
most of the data primarily restricted to observational and retrospective subgroup analyses. 
This article aims to review the epidemiology and prevalence of HTN in Hispanics, 
clinical characteristics, treatment strategies and specific challenges such as lack of access 
to health care, low socioeconomic status, language barriers and degree of acculturation.  
 
 
Demographics 
Unlike other ethnic groups, Hispanics represent the only ethnic group defined not by 
geographic origin but rather by common language, (5,6) which explains the heterogeneity 
and diversity of this group. In 2010 Mexican-Americans were by a large margin the most 
AC
CE
PT
ED
 M
AN
US
CR
IPT
ACCEPTED MANUSCRIPT
numerous Hispanic sub-group (63%), compared to Puerto-Ricans (9.2%), Cubans (3.5%), 
Salvadorans (3.3%) and Dominicans (2.8%), and the remaining 18.2% self-defined as 
other-Hispanic or Latino origin. According to the 2010 Census, 308.7 million people 
resided in the US of which 50.5 million (or 16 percent) were self-described Hispanic or 
Latino. Additionally, more than half of the population growth in the US over the last 
decade was attributable to the increase in the Hispanic population. (1) In the last decade, 
the Hispanic population grew by 43 percent, which was four times the growth in the total 
population. Population growth between 2000 and 2010 varied by Hispanic sub-group; the 
population of people of Mexican descent increased by 54 percent from 20.6 million to 
31.8 million. Mexican-Americans accounted for about three-quarters of the total growth 
(15.2 million) in the Hispanic population during the last decade. Puerto Ricans grew by 
36 percent, increasing from 3.4 million to 4.6 million, Cubans increased by 44 percent, 
growing from 1.2 million in 2000 to 1.8 million in 2010 and Hispanics who reported 
other origins increased by 22 percent, from 10.0 million to 12.3 million. 
 
HTN Prevalence, Awareness and Control 
The prevalence of HTN varies among racial/ethnic groups, with the highest rate seen 
among blacks (40.4%) when compared with whites (27.4%) and Mexican-Americans 
(26.1%).  (1,5) However with the continued growth of the Hispanic population in the US, 
the number of Hispanic patients at risk for HTN and its CV consequences is rapidly 
going to overshadow both blacks and whites. Moreover data from the National Health 
and Nutrition Examination Survey for the period 2003–2010 demonstrate disparities in 
blood pressure (BP) control for whites (48.6%), blacks (43.0%), and Mexican-Americans 
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(35.5%) (Figure 1). Additionally, among those with HTN, the proportion with previously 
defined stage 2 HTN was greater for Mexican-Americans (19.2%) and blacks (17.7%) 
compared with whites (12.3%). (1) 
 
Risk Factors for HTN 
The significant risk factors for the development of HTN in the general population have 
been well established including age, tobacco use, obesity, T2D, sedentary lifestyle, poor 
nutritional status (low intake of fruits and vegetables), decreased potassium intake and 
excessive sodium and alcohol consumption. (7) However, in the Hispanic population as 
in other minority immigrant populations, a unique risk factor has been identified; 
acculturation and duration of time in the US. (8) While much of the epidemiological data 
in the Hispanic population assumes a homogenous population, it has been obtained from 
a predominantly Mexican-American cohort, and does not consider the heterogeneous 
diversity of Hispanics in the US.  Interestingly, recent data suggests that while the major 
risk factors for the development of HTN exist within the Hispanic population, there are 
subtle yet important differences between various ethnic and cultural Hispanic groups. (8)  
(Figure 2) 
 
T2D and Metabolic Syndrome(MetS) 
T2D is almost twice as prevalent among Hispanics and carries significantly higher 
mortality compared to Non-Hispanic whites. (9) However Daviglus et al. recently 
reported a difference in the prevalence of T2D within Hispanic sub-groups, Mexican-
Americans and Dominican have the highest rates (19% and 18%, respectively) followed 
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closely by those of Central American descent (17%), then Cubans (13%) and the lowest 
prevalence in Hispanics of South American heritage (10%). (8) The increased prevalence 
of T2D in Hispanics is not limited to adults and is much more prevalent in Hispanic 
adolescences (age 10-19) compared to whites. Furthermore the incidence of newly 
diagnosed T2D is highest among Hispanics. (10) With the increasing obesity epidemic 
risk for CV diseases (CVD) is not limited to T2D, the prevalence of MetS is high in the 
Hispanic population as well. Hispanic adolescents have more than twice the risk of 
developing MetS compared to non-Hispanic whites (7.6% vs. 3.1%, respectively). (11) In 
Hispanic adults there exists disparity in the prevalence of MetS between sexes. Hispanic 
women have a 22% higher age-adjusted risk for MetS compared to their male 
counterparts. Mexican-American men have a similar risk of MetS as non-Hispanic 
whites, but higher than non-Hispanic blacks. However, Mexican-American women have 
the highest prevalence of MetS (41%) compared to 32% and 39% for non-Hispanic 
whites and non-Hispanic blacks, respectively. (11) In a recent meta-analysis (12), MetS 
carried twice the risk (RR:2.35) for all- cause mortality and CVD (including  CVD death, 
myocardial infarction and stroke).  Finally estimates from the National Health Instrument 
Survey data (1984-2000), US Census bureau data (2000) and an epidemiological study of 
T2D-associated mortality (13) demonstrated that Hispanic children born in 2000 had 
almost twice the residual life-time risk of developing T2D compared to non-Hispanic 
whites, and it was slightly higher than non-Hispanic blacks.  
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Obesity 
Obesity, a major risk factor for HTN and CVD, continues to be a pervasive epidemic in 
the US. The prevalence of over-weight / obesity in the US has risen to a staggering 64% 
of children and 31% in adults. (13) However Hispanics are 20% more likely to be obese 
compared to non-Hispanic whites, the prevalence of obesity is even greater in Mexican-
American women, who are 40% more likely to be obese compared with non-Hispanic 
white women. This disparity is even greater in children, with Mexican-American children 
having 60% increased risk of being overweight compared to non-Hispanic whites. (9) 
Within Hispanic sub-groups, there are subtle differences in the prevalence of obesity, 
with Hispanics of Puerto Rican and Dominican descent having greater prevalence of 
obesity, with the lowest rates in those of South American descent. (8) The obesity 
epidemic is the driving force behind the increased incidence of T2D, (14) is associated 
with higher CV risk (HTN, dyslipidemia), lower school performance, increased tobacco 
use and less healthy life-styles. (15) 
Nutrition and Physical Activity  
Nutrition and exercise are both significant risk factors for HTN and also contribute to the 
growing obesity epidemic. Researchers have found that the quality of nutritional intake is 
as important as the total calories consumed to obesity. Foods such as nuts, whole grains, 
fruits and vegetables are associated with weight loss, while sugar, refined grains, sweets 
and deserts are related to weight gain. (16) Data consistently show that Hispanics have 
greater intake of fruits and vegetables, (17) with little difference in total caloric 
consumption compared to Non-Hispanics Whites, (18) yet have higher rates of obesity. 
(11) [Table 1] One possible explanation for the disparity between nutrition and obesity 
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among Hispanics may be a lack of physical activity and exercise.  Hispanics are less 
likely to meet guideline recommended levels of daily physical activity. (19) Hispanic 
children spend a higher percentage of time using electronic devices or watching 
television, activities that have been shown to have significant impact on physical activity, 
nutritional intake and obesity. (11) Data obtained from The Hispanic Community Health 
Study/ Study of Latinos demonstrated that level of physical activity did not differ 
significantly by sub-group, which agrees with data from Daviglus ML et al. (8). However 
acculturation resulted in a shift in the type of physical activity in Hispanics. While 
acculturation resulted in greater Leisure Time Physical Activity, there was a decline in 
Travel and Occupational related physical activity, resulting in no significant change in 
overall physical activity. (20) Furthermore data that suggests that physical activity and 
exercise has less effect on HTN for Hispanics than Non-Hispanic whites and Non-
Hispanic blacks. In this study the frequency of exercise directly correlated with 
significantly lower prevalence of HTN, however, this correlation was not as strong (or 
significant) in the Hispanic population. (21) 
Tobacco Use 
Current evidence supports lower prevalence of tobacco use among Hispanics compared 
to non-Hispanic whites and non-Hispanic blacks, particularly comparing Hispanic 
women with non-Hispanic whites or blacks. (22) However, as with previously discussed 
risk factors, there are differences in Hispanic sub-groups. Tobacco use is highest among 
Hispanics of Cuban and Puerto Rican descent and lowest among Dominican men and 
Central American Women. (12)  
Acculturation 
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While the traditional risk factors for HTN contribute to the disease burden in the Hispanic 
population, the disparities noted in nutritional intake, effect of PA/exercise and lower 
prevalence of tobacco use, suggest that there are environmental and genetic factors 
associated with ethnicity that must also contribute to the development of HTN. In a 
recent publication from Daviglus et al., the prevalence of HTN and CV risk factors 
(TDM, obesity and smoking) varied between Hispanic sub-groups living in the US. The 
same study shows the negative effect of acculturation on CV risk factors in the Hispanic 
population, as well as an increased number of CV risk factors directly correlated with 
lower socio-economic status, acculturation, decreased physical activity and poor 
nutrition. (8) While acculturation was shown to have a negative effect on the rates of 
HTN in the Hispanic Health and Nutrition Examination Survey (23), it has also been 
shown to have positive effects on the rates of awareness, treatment and control of HTN 
(24). Interestingly while Hispanics with higher self-reported rates of acculturation report 
higher health self-ratings, unfortunately it did not translate into higher rates of control of 
HTN (25). 
Genetics 
 With relatively little data on genetic factors of HTN, there is sufficient evidence 
to support the belief that there exist differences in the epidemiology of HTN between 
Hispanics and Non-Hispanics.  Data from the Viva La Familia Study found genetic links 
between CV risk (26) and fasting plasma glucose (27). A meta-analysis has shown a 
genetic association between HTN and angiotensin-converting enzyme (ACE) activity 
(28,29). Data published from Mexican-Americans have linked HTN with genetic loci 
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associated with several risk factors for HTN, (30) including MetS (31), high serum uric 
acid (32) and environmental lead exposure (33). 
 
Socioeconomic Status  
Understanding of the risk factors and epidemiological data provides only part of the 
information necessary to understand the complexities of HTN in the Hispanic population. 
Socioeconomic factors such as education, income and access to regular health care have 
significant impact on the awareness, treatment and control of HTN in Hispanics. The 
most recent data from the US Census Bureau indicates a significant disparity in health 
care insurance for Hispanics in the US. Hispanics are more likely to be uninsured 
compared to Non-Hispanic whites and blacks, 29% (15.5 million), 19% (13 million) and 
11% (22 million), respectively. (34) The same data demonstrated that lack of insurance is 
higher in non-citizens and foreign-born Hispanics. The US Census Bureau has 
consistently shown that income is directly related to lack of health insurance and that 
Hispanics traditionally have the lowest median income. (34) Beyond ethnic/racial 
disparity, other factors, such as income, education, foreign born and non-citizens, that 
often affect Hispanic Americans have been linked to lack of health care. (35) This data 
demonstrates some of the many factors that contribute to the overall poor awareness and 
control of HTN in Hispanics compared to non-Hispanic whites. (36) Furthermore data 
from the National Health and Nutrition Examination Survey has linked lack of regular 
medical care to the risk of developing HTN. (37) It has been shown that Hispanics with 
uncontrolled HTN are less likely to have insurance coverage compared to non-Hispanic 
white and black patients. (38) Disparities in health insurance coverage can been seen 
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among Hispanic sub-groups, Hispanics of Mexican-American and Central American 
descent are less likely to have health insurance compared to those of Puerto Rican and 
Cuban descent. (39) Socioeconomic status has been linked to sedentary life-style, 
childhood obesity, prevalence of CVD, delayed medical care, tobacco use and decreased 
life expectancy. (40)  
 The lack of access to healthcare is exacerbated by the lower quality of care 
provided to minorities and those of lower socioeconomic status.  The National Center for Health Statistics project has reported that quality of care obtained is associated with 
lower income and minority status. (41) The same data has shown that language barriers 
between patients and healthcare providers contribute to decreased quality of care, patient 
satisfaction, physician satisfaction and safety. (41) Language barriers have been linked to 
decreased adherence to medical therapy, (42) decrease the discussion of medication side 
effects, (43) lower utilization of preventive screening, (42) and contribute to negative 
health outcomes (44) and higher provider mistrust. (45) 
 
Pharmacology Therapy  
 
Data on anti-HTN therapy in Hispanics remains limited [Table 2]. Their 
underrepresentation in large HTN trials and the absence of specific recommendations in 
the recently published (Joint National Committee) JNC 8 (46) underscore the need for 
further studies focusing on this population. The Antihypertensive and Lipid-lowering 
Treatment to Prevent Heart Attack (ALLHAT) Trial (47,48) was the first study to include 
a large number of Hispanics. In brief, the ALLHAT trial aimed to investigate whether an 
ACE inhibitor (lisinopril) to a calcium channel blocker (amlodipine) was superior to a 
thiazide diuretic (chlorthalidone) in preventing CV complications of HTN in high-risk 
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individuals. (47,48) In this study, 15.7% (n = 5246) Hispanics were enrolled.  Despite a 
lower rate of HTN control at enrollment, Hispanics had higher control rates than non-
Hispanic whites and blacks after 6 months of treatment, and significantly higher odds of 
achieving HTN control than non-Hispanic whites within 24 months of follow-up. (47,48) 
Similarly, investigators from the INVEST trial (49) compared the efficacy of a verapamil 
sustained- release (SR) strategy to that of an atenolol strategy in 8045 Hispanic HTN 
patients with respect to adverse CV outcomes and BP control. The major finding of this 
study was that a better BP control was achieved in Hispanic patients when compared with 
non-Hispanic patients. Moreover, this better BP control in Hispanic patients was 
accomplished with fewer drugs compared with the non-Hispanic patients. In addition to 
lower CV adverse outcomes in the Hispanic patients, BP management with either the 
verapamil SR or the atenolol strategies resulted in similar BP reduction, and with the 
exception of lower risk of new-onset T2D in the verapamil SR strategy. (49) With a 
increased risk of adverse metabolic adverse outcomes like MetS and T2D, beta-blockers 
may not be ideal agents for the treatment of HTN in Hispanics. (50,51) In contrast, ACE 
inhibitors and angiotensin receptor blockers could particularly be attractive agents for the 
treatment of HTN in the Hispanic population, as they have been associated with a 25% 
reduction in the risk of T2D when used in the general hypertensive population. (52) In 
this regard, a single-arm trial (53) designed to examine the efficacy and safety of fixed-
dose combinations of irbesartan and hydrochlorothiazide in a multiethnic group of 
patients with uncontrolled systolic HTN (total population 844 patients, 14% Hispanics) 
treatment with hydrochlorothiazide (HCTZ) 12.5 mg/d for 2 weeks followed by a 
combination of irbesartan 150 mg and HCTZ 12.5 mg/d for 8 weeks followed by an 
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additional 8 weeks of irbesartan 300 mg and HCTZ 25 mg/d resulted in mean reductions 
of 22.9±13.2 mm Hg in systolic BP (P<.001) and 10.6±8.1 mm Hg in diastolic BP 
(P<.001) from baseline. These reductions were similar to the BP reductions achieved in 
blacks and whites. (53) Similar results were shown in the Valsartan-Managing Blood 
Pressure Aggressively and Evaluating Reductions in hsCRP (Val-MARC) study (54, 55) 
where valsartan/HCTZ was more effective than valsartan alone in lowering BP among 
Hispanics. (54, 55) In summary, the available data suggest that the rennin angiotensin 
aldosterone system antagonists agents alone or in combination with diuretics, seem to be 
an effective treatment strategy for Hispanics HTN patients. 
Conclusions / Future Directions 
As demonstrated by the limited data available from clinical trials, the pressing problem 
for the management of HTN in the Hispanic population is not finding adequate and 
effective therapy, but identifying HTN and providing access to care for the Hispanic 
population. The higher prevalence of uncontrolled HTN is directly related to lack of 
access to healthcare, which is partially due to lower socio-economic status, language 
barriers and education. With limited data on medication class effect on HTN control and 
CV outcomes in Hispanics, we cannot make treatment recommendations. However, as 
shown previously, presence of comorbidities such as obesity, MetS, dyslipidemia (56), 
and T2D in Hispanics may aid in the choice of a specific anti-HTN therapy.  
While future clinical trials should endeavor to separate the heterogeneous Hispanic 
population into sub-groups, this may not be feasible for recruitment purposes. However, 
practitioners should keep in mind the differences in risk factor profiles among the 
Hispanic sub-groups when evaluating and treating HTN.  
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Drug therapy cannot be the sole treatment strategy to deal with the inevitable 
increase in disease burden over the next decades. Efforts to improve patient education 
about the importance of physical activity and risk factor modification and access to 
regular medical care in the Hispanic population must be the cornerstone of any treatment 
strategy. As the Hispanic population continues to grow in the US, the health and well-
being of this heterogeneous group of people will be ultimately reflected on the health of 
the nation.  
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Figures 
 
Figure 1: Ethnic disparity in prevalence, awareness, treatment and control of hypertension among adults in the US, adjusted by age. (Adapted from CDC/NCHS, National Health and Nutrition Examination Survey, NCHS Data Brief Number 107, October 2012) 
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Figure 2: Prevalence of CV / HTN Risk Factors in Hispanic Population – Adapted 
from NHANES 2013, Office of Minority Health, CDC and Daviglus ML et al. (4). 
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Tables 
 
Table 1: Nutrient Intake and Physical Activity by Race / Ethnicity [17, 18] 
Risk Factor Non- 
Hispanic 
White 
Non-
Hispanic 
Blacks 
Mexican 
American 
All 
Hispanics 
Nutrition (13)     
Calorie, kcal.day 2150 2202 2138 2124 
Protein g/day 83.3 79.7 84.8 84.2 
Carbohydrate, g/day 257 254 277 273 
Total Fat, g/day 81.4 78.8 73.7 73.1 
Saturated Fat, g/day 26.9 25.2 23.7 23.6 
Dietary Fiber. g/day 17.3 13.6 20 18.4 
Sodium, g/day 3.6 3.3 3.3 3.4 
Potassium, g/day 2.9 2.3 2.8 2.7 
Alcohol, g/day 12.3 11.4 7.9 8.9 
Fruits and Vegetable, cup 
equivalent/day (57) 
    
Men 3.04 2.49 3.26 - 
Women 2.58 2.46 3.03 - 
     
Physical Activity (PA) 
 
    
Met guideline recommended 
regular leisure-time PA, % (7) 
22.9 16.6 - 15.7 
 
Adults meeting both aerobic 
and muscle strengthening 
guidelines, % (14) 
21 21 - 18 
Leisure-Time Physical 
Inactivity, %(58) 
    
Men 18.4 27.0 - 32.5 
Women 21.6 33.9 - 39.6 
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Table 2: Clinical Trials in Hypertension with large Hispanic Subgroup Included 
 
(See attached separate document for Table 2 in Landscape format) 
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Table 2: Clinical Trials in Hypertension with large Hispanic Subgroup Included 
 
 
Trial 
/Paper 
Title Study Design Ethnicity 
n (%) 
Treatment Outcomes Results 
   Hispanic Non-
Hispanic 
  
Margolis 
et al. (48) 
BP Control in 
Hispanics in 
ALLHAT 
Hispanic 
subgroup 
analysis of 
the ALLHAT 
randomized 
active control 
trial. Patients 
with 
hypertension 
and  ≥  1  CHD  
risk factor (N 
= 33,357) 
6329 
(19.4) 
26 313 
(80.6) 
Amlodipine 2.5-
10mg/day 
Lisinopril 10-40 
mg/day 
Doxazosin 2-8 
mg/day 
Chlorthalidone 
12.5-25 mg/day 
BP control 
(SBP / DBP 
< 140/90 
mm Hg) 
Cooper-
DeHoff 
et al. (49) 
BP control and 
cardiovascular 
outcomes in 
high-risk 
Hispanic patients 
– findings from 
INVEST 
Randomized, 
open-label 
trial in 
patients with 
CAD and 
hypertension. 
Subgroup 
analysis of 
the INVEST 
trial. (N = 
22,576) 
8045 
(35.6) 
14,531 
(64.4) 
Verapamil SR 
240-360 
mg/daily 
Atenolol 50-100 
mg/day 
Trandolapril or 
HCTZ added to 
achieve BP goal. 
Risk of 
adverse CV 
outcomes 
(primary); 
BP control 
(SBP/DBP 
<130/85 
mmHg for 
patients 
with T2DM 
or renal 
impairment: 
<140/90 
mmHg for 
all others). 
Ofili et 
al. (53) 
Irbesartan/HCTZ 
fixed 
combinations in 
patients of 
different 
racial/ethnic 
groups with 
uncontrolled 
systolic BP on 
monotherapy 
Subgroup 
analysis of 
INCLUSIVE 
open-label, 
single-arm, 
sequential 
treatment 
trial in 
patients with 
uncontrolled 
BP (N=825) 
119 
(14.1) 
725 (85.9) HCTZ 12.5 
mg/day 
Irbesartan/HCTZ 
150/12.5 mg/day 
or 300/25 
mg/day 
Primary 
outcome 
was mean 
change in 
SBP from 
baseline at 
18 weeks; 
secondary – 
mean 
change in 
DBP at 18 
weeks. 
SBP/DBP 
control at 
weeks 2, 10 
and 18.  
 
